Intalith Tablet
Lithium Carbonate
300mg
Intas Pharmaceuticals Ltd.
| Pack size | 1 |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 2.35 NPR |
Available as:
Indications
Intalith Tablet is used for:
Bipolar disorder, Mania, Recurrent unipolar depression
Adult Dose
Oral
Mania; Bipolar disorder; Recurrent unipolar depression
Adult: Treatment and prevention: Initially, 400-1,200 mg daily in 1-2 divided doses.
Serum lithium should be monitored 12 hours after dose, twice weekly until serum concentration and clinical condition stabilize, and every other month thereafter
Desirable range for serum lithium: 0.6-1.2 mEq/L; although higher serum concentrations may be needed, not to exceed 1.5 mEq/L
Child Dose
Renal Dose
Renal impairment:
CrCl (ml/min) Dosage Recommendation
10-50 50-75% of normal dose.
<10 25-50% of normal dose.
Administration
Should be taken with food.
Contra Indications
Renal insufficiency, cardiovascular insufficiency, Addison\'s disease and untreated hypothyroidism are all contraindications to lithium therapy.
Precautions
Decreased tolerance to lithium has been reported to ensue from protracted sweating or diarrhoea and, if such occur, supplemental fluid and salt should be administered under careful medical supervision and lithium intake reduced or suspended until the condition is resolved.
Lactation: Drug is excreted in breast milk; use not recommended
Pregnancy-Lactation
Interactions
Reduced serum levels with carbonic anhydrase inhibitors, chlorpromazine, sodium-containing preparations, theophylline, urea. Enhanced hypothyroid effects with iodine salts. Enhanced effects of neuromuscular-blocking agents. Reduced pressor response to sympathomimetics.
Potentially Fatal: Increased risk of lithium toxicity with ACE inhibitors, angiotensin receptor antagonists, loop diuretics, metronidazole, phenytoin. Increased risk of neurotoxicity with carbamazepine, calcium-channel blockers, haloperidol, methyldopa, phenothiazines, SSRIs, TCAs. Increased serum levels with COX-2 inhibitors, NSAIDs (except sulindac, aspirin), tetracyclines, thiazide diuretics. Increased risk of encephalopathy with haloperidol. Increased risk of serotonin syndrome with sibutramine. Fatal malignant hyperpyrexia may occur when used with MAOIs.
Adverse Effects
Side effects of Lithium Carbonate :
>10%
Leukocytosis (most patients),Polyuria/polydypsia (30-50%),Dry mouth (20-50%),Hand tremor (45% initially, 10% after 1 year of treatment),Confusion (40%),Decreased memory (40%),Headache (40%),Muscle weakness (30% initially, 1% after 1 year of treatment),Electrocardiographic (ECG) changes (20-30%),Nausea, vomiting, diarrhea (10-30% initially, 1-10% after 1-2 years of treatment),Hyperreflexia (15%),Muscle twitch (15%),Vertigo (15%)
1-10%
Extrapyramidal symptoms, goiter (5%),Hypothyroidism (1-4%),Acne (1%),Hair thinning (1%)
Frequency Not Defined
Coma,Lethargy,Seizures,Renal toxicity
Mechanism of Action
Inhibits postsynaptic D2 receptor supersensitivity. Alters cation transport in nerve and muscle cells and influences reuptake of serotonin or norepinephrine. Inhibits phosphatidylinositol cycle second messenger systems.
Note
Intalith 300mg Tablet manufactured by Intas Pharmaceuticals Ltd.. Its generic name is Lithium Carbonate. Intalith is availble in Nepal.
Farmaco Nepal drug index information on Intalith Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.